New insights on heart disease and menopause
As if hot flashes, mood swings, uncomfortable sex, and a host of other symptoms weren't enough to deal with, menopause is also a time when a woman's risk of cardiovascular disease shoots up to match men her age. Although scientists have known this for some time, new research is beginning to shed light on the complex link between heart disease and menopause, Hone Health reports.
One factor is declining estrogen levels during perimenopause, which removes some of the hormone's cardioprotective effects, physician Ella Ishaaya M.D. says. "Estrogen downregulates inflammatory markers, prevents buildup of lipids and LDL, and a number of other things." Once that happens, your body shifts toward a more androgenic profile—meaning it's more like that of a man's—and cardiovascular risks rise.
But you don't have to accept these changes. New research has identified screenings and medications that may help detect and address heart disease sooner, potentially leading to better outcomes.
Most of us know high levels of triglycerides and LDL (bad) cholesterol are red flags for heart health. Recently, another lesser-known cardiovascular biomarker, lipoprotein (a) or Lp(a), has also been making headlines.
Lipoprotein (a) is structurally similar to LDL but has a second protein called apolipoprotein(a) attached to it, cardiologist Anurag Mehta, M.D., explains. "It's associated directly with the [heightened] risk of cardiovascular disease, heart attack, stroke, and a heart valve problem called aortic stenosis," he adds.
While Lpa levels remain relatively stable throughout your life, they increase after menopause. It's unclear why, Mehta says. "There's some thought that estrogen levels [regulate] levels of Lp(a)."
Genetics also play a role, making it difficult to manage Lp(a) levels through lifestyle changes alone. "The impact of menopause and lifestyle factors like diet and exercise tends to be small," Mehta says. Additionally, "there are well-known race and ethnic differences in Lp(a) levels." Black people generally have levels three times higher than white people, and South Asians twice as high.
Fortunately, hormone replacement therapy (HRT)—also called menopause hormone therapy (MHT)—appears to help lower lipoprotein(a). Other emerging therapies may be available in the coming years, including the following medications:
Antisense oligonucleotides (ASOs) inhibit the production of apolipoprotein(a) and reduce Lpa by up to 80 percent or more in trials.
RNAi are small, interfering RNA molecules that silence the gene that encodes Lp(a). An early-stage clinical trial showed a single dose decreased Lp(a) by up to 98 percent.
If further testing confirms the safety and efficacy of these and other medications, FDA approval is anticipated in the next two to three years, Mehta says. Studies will have to show that these drugs can lower Lp(a) and improve cardiovascular outcomes.
Getting a lipoprotein(a) screening
Although one in five people have high Lp(a) levels, a standard lipid panel doesn't measure this biomarker. European and Canadian guidelines recommend everyone be screened once. But in the U.S., doctors typically only recommend checking your lipoprotein(a) if:
You're younger than 65 and have had a heart attack
You have a family history of early cardiovascular disease
You have high LDL that can't be controlled by statins
If you're interested in testing, talk to your healthcare provider about your risk factors.
Calcifications in the coronary arteries indicate plaque buildup, or atherosclerosis, which can lead to heart disease. A coronary artery calcium (CAC) test can help assess your risk. It's a CT scan that measures calcium in the arteries supplying blood to the heart, with a higher score indicating a greater risk of heart problems.
"Think of the coronary arteries as a plumbing system," physician Ella Ishaaya, M.D. says. "If you develop some gunk in your faucet, the water will still pass." But as the gunk forms and gets larger, it will eventually clog the faucet, and only a little water will pass through.
The heart operates similarly. "The coronary arteries supply blood to the heart," Ishaaya says. A build-up of calcium and other inflammatory cells could calcify and become hard plaque. If this plaque ruptures or erodes in the coronary artery, it can cause a blood clot to form, which blocks blood flow to your heart and causes a heart attack.
Coronary artery calcification accelerates after menopause, increasing these risks. In a recent study led by Ishaaya, researchers found among patients taking statins, CAC scores increase faster in postmenopausal women compared to men of the same age, showing a median rise of 31 points in a year—roughly double the rate for men. One possible explanation, Ishaaya says, is the decline in cardioprotective estrogen.
When to consider a CAC test
Though Ishaaya says anyone at risk for heart disease should get a CAC test, your insurance may not cover the CT scan needed to spot it. The American College of Cardiology and American Heart Association guidelines recommend a CAC test for people with an atherosclerotic cardiovascular disease (ASCVD) risk of 7.5 to 20 percent to determine if statins would be recommended.
Here's how CAC scores are categorized:
0 = No disease
1-99 = Mild disease
100-399 = Moderate disease
400+ = Severe disease
"Anything greater than zero means you have a degree of calcium buildup in your heart, so you should make lifestyle modifications to mitigate that risk," Ishaaya says. "Once your score is in the double digits, we think about statin therapy." However, if you have a family history of atherosclerosis or have multiple risk factors for the condition, statins may be a great preventive measure—regardless of your CAC score.
Hot flashes aren't just annoying—they may indicate a higher risk of heart problems. In a study published in the Journal of the American Heart Association in 2021, women whose hot flashes persisted for an average of four annual checkups had a 77 percent increased risk of cardiovascular disease. Researchers aren't sure why, but women with hot flashes often have higher levels of cholesterol, LDL, triglycerides, blood pressure, and insulin resistance than women who don't.
Steps to take if you have hot flashes
Using hormone replacement therapy (HRT) to reduce cardiovascular risk during menopause remains a topic of debate. The Menopause Society doesn't recommend HRT for heart health alone in women who enter menopause at the average age (around 52), a position supported by several studies.
However, some studies suggest estrogen therapy may reduce the risk of heart disease and death in healthy women under 60 who are within 10 years of menopause.
Ultimately, "we need more data," gynecologist Brandye Wilson-Manigat, M.D., FACOG, says. "There are so many formulations of estrogen now; the dosings are different, and how you administer the medications is different. All of that may have some impact on the benefits and risks of cardiovascular disease in using them."
Deciding whether or not to take HRT—and for how long to take it—should be a conversation between you and your physician. They will take into consideration your age, how long you've been in menopause, your personal and family history of heart health, other medications you're taking, and more.
Although you can't avoid menopause, you can take action to prevent cardiovascular disease. "Making lifestyle and diet changes can have a very beneficial effect [on your heart health]," Mehta says, even if you have high Lp(a) levels or a family history. Consider these expert-backed recommendations:
Get screened regularly
In addition to the biomarkers mentioned above, get your lipid panel checked annually to stay on top of your total cholesterol, LDL, HDL, and triglycerides. Keep in mind: You can have normal cholesterol levels and a high CAC score.
Manage other conditions
Hypertension, diabetes, obesity, and high cholesterol—alone or combined—increase the risk of heart disease. Mehta recommends working with your medical team to manage these conditions as best you can through lifestyle changes and medication.
Stay active
Research shows that higher levels of physical activity are linked to a lower risk of cardiovascular disease. Aim for 150 minutes of moderate aerobic exercise or 75 minutes of vigorous aerobic exercise weekly, plus at least two days of strength training per week.
Eat a heart-healthy diet
The Mediterranean, DASH, and plant-based diets have the most evidence for preventing heart disease. Prioritize minimally processed foods such as vegetables, fruits, legumes, nuts, lean proteins, and healthy fats, including olive oil and avocados.
Talk to your doctor about treatment options
The best medication for women going through perimenopause is the one that's unique to their symptoms and health history—meaning, it requires a conversation with your doctor. For anyone with elevated LDL cholesterol levels or a high CAC score, statins are typically recommended. "Statin therapy is one of the mainstays of treatment that we have to lower cardiovascular risk," Mehta says.
This story was produced by Hone Health and reviewed and distributed by Stacker.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Miami Herald
27 minutes ago
- Miami Herald
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here IRVINE, CA / ACCESS Newswire / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: 83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS).9.1 point average rVCSS improvement among the responder cohort.A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS).Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym).Among the subjects (n=30), a 100% valve patency rate. All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. "These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options," said Robert Berman, enVVeno Medical's Chief Executive Officer. "Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option." Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, "Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve" today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation


Miami Herald
28 minutes ago
- Miami Herald
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside chat at 9:00 AM Eastern on Tuesday, June 10, 2025, as part of Lytham Partners' spring 2025 Spotlight Series. The discussion will focus on Jaguar's ongoing efforts to further its orphan disease development programs. Participation Instructions for Jaguar Health's Virtual Fireside Chat During Lytham Partners Spring 2025 Spotlight Series When: Tuesday, June 10, 2025 from 9:00 - 10:00 AM Eastern Where: Online (Click Here). The fireside chat will also be available for replay following the event. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will participate in a virtual fireside chat June 10, 2025 as part of Lytham Partners' spring 2025 Spotlight Series. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: hello@ SOURCE: Jaguar Health, Inc.

Miami Herald
29 minutes ago
- Miami Herald
JBA AI Earns FDA SaMD Recognition
A New Era of Accessible Health Monitoring GARDEN GROVE, CALIFORNIA / ACCESS Newswire / June 9, 2025 / JBA AI, the flagship health-tech division under AQ Pharmaceuticals, Inc. and JBA Brands, proudly announces several major global milestones in its mission to make preventive healthcare more accessible, intelligent, and affordable. JBA AI has been officially recognized by the United States Food and Drug Administration (FDA) as a Software as a Medical Device (SaMD). In addition, the platform has now received Class B Medical Device approval from Vietnam's Ministry of Health. These achievements affirm the platform's safety, clinical effectiveness, and international credibility. The JBA AI mobile application is already available globally for Android users and will soon be released on iOS. It enables contactless, non-invasive vital signs monitoring directly through smartphones or tablets. In just 60 seconds, the app delivers insights on over nine key health metrics. These include heart rate, heart rate variability, blood oxygen saturation, respiratory rate, stress index, and estimated glucose and blood pressure trends. This is achieved using AI-powered facial signal analysis through camera-based remote photoplethysmography technology. Expanding its impact even further, JBA AI has partnered with one of Vietnam's largest financial institutions, which serves more than 30 millions members. Together, they are preparing to launch JBA AI nationwide, making preventive health monitoring more accessible through a trusted and widespread digital network. "JBA AI is more than a health app - it's a certified medical device. Recognized by both the FDA and Vietnam's Ministry of Health," said Tracy Trang Nguyen, founder and CEO of JBA AI. "We're proud to deliver trusted, clinically guided tools for daily health monitoring worldwide." Nguyen is a Vietnamese American engineer and wellness industry leader who developed JBA AI after surviving cancer. Her personal health journey inspired her to combine advanced artificial intelligence with affordable wellness solutions. Under her leadership, JBA AI complements other products within the JBA Brands portfolio, such as GlucoTrojan, Joint Revive Fucoidan, and Vegan Collagen, to form a fully integrated health ecosystem. JBA AI is already gaining traction and is starting to expand into pharmacies, corporate wellness programs, public health campaigns, and family clinics across the United States, Vietnam, and other countries. The platform's franchise-ready model supports rapid local deployment while keeping costs low and impact high. It is designed to help people monitor their health in real-time, without the need for needles, wearable devices or clinic visits. JBA AI is currently welcoming franchisees, affiliates, and institutional partners to help bring this technology to communities around the world. Whether at home or in partnership with healthcare providers, JBA AI is redefining preventive care through data-driven technology and a compassionate approach to well-being. Contact Information Catherine Marino Marketing Managercat@ 714 903 1009 SOURCE: AQP One, Inc. press release